The biochemical properties of tumor cells and their metabolism are abnormal, so the substances that are qualitatively or quantitatively changed in the body fluids, excretions and tissues of tumor patients are tumor markers. Tumor markers are mainly used clinically for the discovery of primary tumors, the screening of high-risk groups of tumors, the differential diagnosis of benign and malignant tumors, the judgment of the degree of tumor development, the observation and evaluation of tumor treatment effects, and the prediction of tumor recurrence and prognosis, etc. .

CA50

CA50 is a sialic acid ester and sialic acid glycoprotein. It is a non-specific broad-spectrum tumor marker with certain cross-antigenicity with cancer antigens 19-9. It is mainly used for pancreatic cancer, colon/rectal cancer, and gastric cancer. auxiliary diagnosis. Generally not present in normal tissues, when cells become malignant, glycosylase is activated, resulting in changes in cell surface glycosyl structure and becomes a CA50 marker. Other lung cancer, liver cancer, ovarian or cervical cancer, bile duct cancer, bladder cancer, etc. all have a large percentage increase. In addition, some ulcerative colitis, liver cirrhosis, melanoma, lymphoma, autoimmune diseases, etc. can also see increased CA50.

Cat.No.	Name	Application-Platform	Product Description
HA110-1MB	CA50 Antibody	Detection-CLIA	Mouse Antibody, Sialylated Lewis and lacto-N-tetraose
HA110-1H	CA50 Antibody	Capture-CLIA	Humanized, Sialylated Lewis and lacto-N-tetraose

CA242

CA242 is a sialylated glycosphingolipid antigen that is almost always expressed together with CA50, but the two are recognized by different monoclonal antibodies. It has been clinically used for the diagnosis of digestive tract malignant tumors, especially pancreatic cancer and colorectal cancer. Compared with CA19-9 and CA50, the new generation of CA242 has the sensitivity and specificity in pancreatic cancer, gallbladder cancer and digestive tract cancer. The sex is higher (CA50, CA19-9 are susceptible to liver function and cholestasis, and false positives often occur in benign obstructive jaundice and liver parenchymal lesions).

Cat.No.	Product Name	Application-Platform	Product Description
HA109-1H	CA 242 Antibody	Detection-CLIA	Humanized Antibody
HA109-5M	CA 242 Antibody	Capture-CLIA	Mouse Antibody

CA19-9

CA19-9 is a tumor marker associated with pancreatic cancer, gallbladder cancer, colon cancer and gastric cancer, also known as gastrointestinal tract-associated antigen. CA19-9 and CA242, CA50 have close epitopes, but because of the difference in specificity of monoclonal antibodies, they have different clinical values for diagnosis and monitoring. CA19-9 has high sensitivity and good specificity for pancreatic cancer, and its positive rate is between 85% and 95%, and it decreases with the improvement of the condition after surgery.

Cat.No.	Product Name	Application-Platform	Product Description
HA111-1H	CA 19-9 Antibody	Detection-FIA/CLIA	Humanized Antibody
HA111-1M	CA 19-9 Antibody	Capture FIA/CLIA	Mouse Antibody

CA125

CA125 (MUC16) is an antigen recognized by the monoclonal antibody (named OC125) obtained by immunizing mice with ovarian serous cystadenocarcinoma cell line OVCA433. The relative molecular mass of CA125 ranges from 200,000 to 1,000,000. It is a macromolecular glycoprotein and a glycoprotein complex similar to mucin.
CA125 is most commonly found in the serum of patients with epithelial ovarian tumors (serous tumors) and is absent in mucinous ovarian tumors. Serum CA125 is elevated in 80% of patients with epithelial ovarian tumors, and serum CA125 is associated with disease progression in 90% of patients. The level of CA125 in 95% of healthy adult women is less than or equal to 40U/ml, and attention should be paid to if it rises to more than 2 times the normal value.

Cat.No.	Product Name	Application-Platform	Product Description
HA107-5H	CA 125 Antibody	Detection-CLIA	Humanized Antibody
HA107-4H	CA 125 Antibody	Capture-CLIA	Humanized Antibody

CA15-3

CA15-3 (MUC-1) is a glycoprotein with a molecular weight of about 400KD. The antigenic determinant of CA15-3 is partly sugar and partly polypeptide. In the serum of breast cancer patients, CA15-3 can be significantly increased in 30% to 50% of patients, and the increase in patients with metastatic lesions can reach 80%. It is often used to observe the recurrence of breast cancer after treatment and to monitor the metastasis of breast cancer. CA15-3 can also be combined with CA125 for early diagnosis of ovarian cancer recurrence; when combined with CEA, it can improve the sensitivity and specificity of early diagnosis of breast cancer. In other malignant tumors such as lung cancer, ovarian cancer, colon cancer, liver cancer, etc., serum CA15-3 can also be increased.

Cat.No.	Product Name	Application-Platform	Product Description
HA108-6H	CA 15-3 Antibody	Capture/Detection-FIA/CLIA	Humanized Antibody, similar as DF3
HA108-1M	CA 15-3 Antibody	Detection/Capture-FIA/CLIA	Mouse Antibody, similar as 115D8
HA108-5M	CA 15-3 Antibody	Detection-CLIA	Mouse Antibody, similar as MA552
HA108-4M	CA 15-3 Antibody	Capture-CLIA	Mouse Antibody, similar as MA695